Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199863 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL103129 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL99731 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL202269 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL199590 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL103377 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL201336 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL202134 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL100621 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL101056 | 1.00 | LMNA (0.54) | LMNADNM1ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103068786-B | Cosmetic preparation | COGNIS IP MANAGEMENT GMBH (DE) | 2016-01-20 | — | — | CN | disclosed |
| US-8940943-B2 | Cosmetic preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| EP-2601166-A1 | COSMETIC PREPARATIONS | Cognis IP Management GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131188-A1 | Cosmetic Preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| CN-103068786-A | Cosmetic preparation | COGNIS IP MAN GMBH | 2013-04-24 | — | — | CN | disclosed |
| EP-2426101-A1 | Cosmetic preparations | Cognis IP Management GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012016642-A1 | COSMETIC PREPARATIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-8088922-B2 | Dibenzorylenetetracarboximides as infrared absorbers | BASF AKTIENGESELLSCHAFT (DE) | 2012-01-03 | — | — | US | disclosed |
| WO-2011138743-A1 | USE OF PYROMELLITIC DIIMIDES IN ORGANIC ELECTRONICS AND ORGANIC PHOTOVOLTAICS | BASF SE (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2010111822-A1 | OLIGOCONDENSED PERYLENE BISIMIDES | BASF SE (DE) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112452-A1 | OLIGOCONDENSED PERYLENE BISIMIDES | BASF SE (DE) | 2010-10-07 | — | — | WO | disclosed |
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | US | disclosed |
| CN-101467276-A | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | MAX PLANCK GESELLSCHAFT (DE) | 2009-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | TDO2, C9, CYP3A43 | LMNA 1646/4885DNM1 3365/4885ALDH1A1 627/4885 |
| US-20110042651-A1 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | TPR, ROR1, CA3 | LMNA 2934/4885DNM1 4373/4885ALDH1A1 4792/4885 |
| US-20130131188-A1 | Cosmetic Preparations | CYP1B1, CBR1, ACOX3 | LMNA 1943/4885DNM1 3903/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.